MicroRNAs Can Influence Ovarian Cancer Progression by Dysregulating Integrin Activity.
integrins
miRNAs
ovarian cancer
therapeutic targets
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Sep 2023
08 Sep 2023
Historique:
received:
27
07
2023
revised:
26
08
2023
accepted:
30
08
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Ovarian cancer is a deadly disease that affects thousands of women worldwide. Integrins, transmembrane receptors that mediate cell adhesion and signaling, play important roles in ovarian cancer progression, metastasis, and drug resistance. Dysregulated expression of integrins is implicated in various cellular processes, such as cell migration, invasion, and proliferation. Emerging evidence suggests that microRNAs (miRNAs) can regulate integrin expression and function, thus affecting various physiological and pathological processes, including ovarian cancer. In this article, we review the current understanding of integrin-mediated cellular processes in ovarian cancer and the roles of miRNAs in regulating integrins. We also discuss the therapeutic potential of targeting miRNAs that regulate integrins for the treatment of ovarian cancer. Targeting miRNAs that regulate integrins or downstream signaling pathways of integrins may provide novel therapeutic strategies for inhibiting integrin-mediated ovarian cancer progression.
Identifiants
pubmed: 37760437
pii: cancers15184449
doi: 10.3390/cancers15184449
pmc: PMC10526761
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Cell. 2013 Feb 11;23(2):186-99
pubmed: 23410973
Science. 2007 Mar 16;315(5818):1576-9
pubmed: 17322030
Genome Biol. 2007;8(5):215
pubmed: 17543136
Elife. 2020 Oct 07;9:
pubmed: 33026975
Am J Physiol Cell Physiol. 2015 Oct 1;309(7):C444-56
pubmed: 26224579
Front Endocrinol (Lausanne). 2022 Apr 28;13:886533
pubmed: 35574025
Nat Cell Biol. 2008 May;10(5):593-601
pubmed: 18376396
Gynecol Oncol. 2008 Dec;111(3):478-86
pubmed: 18823650
Pathobiology. 2018;85(1-2):41-49
pubmed: 29020678
Int J Mol Sci. 2022 Apr 15;23(8):
pubmed: 35457198
Front Oncol. 2020 Jul 21;10:1084
pubmed: 32850313
Front Cell Dev Biol. 2019 May 28;7:90
pubmed: 31192208
EMBO Mol Med. 2014 Jun 16;6(7):851-64
pubmed: 24935956
Dev Cell. 2021 Mar 22;56(6):726-746
pubmed: 33756119
BMC Cancer. 2012 Dec 28;12:627
pubmed: 23272653
Biomolecules. 2023 Jan 04;13(1):
pubmed: 36671488
Gynecol Oncol. 2009 Jan;112(1):55-9
pubmed: 18954897
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
Exp Cell Res. 2014 Jan 15;320(2):329-42
pubmed: 24291221
Clin Exp Metastasis. 2022 Apr;39(2):291-301
pubmed: 34822024
Mol Cancer. 2012 May 28;11:36
pubmed: 22640878
Dev Cell. 2018 Feb 5;44(3):284-296
pubmed: 29408235
J Cell Physiol. 2016 Jan;231(1):25-30
pubmed: 26031493
Cancer Res. 2007 Sep 15;67(18):8699-707
pubmed: 17875710
Tissue Cell. 2017 Feb;49(1):95-105
pubmed: 27890350
Physiol Rev. 2019 Oct 1;99(4):1655-1699
pubmed: 31313981
Cell Adh Migr. 2015;9(4):317-24
pubmed: 26241004
Semin Oncol Nurs. 2019 Apr;35(2):151-156
pubmed: 30867104
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Gynecol Oncol. 2021 Nov;163(2):433-444
pubmed: 34253390
Molecules. 2016 Jul 22;21(7):
pubmed: 27455225
Cancers (Basel). 2022 Jan 14;14(2):
pubmed: 35053578
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
EMBO J. 2018 Apr 3;37(7):
pubmed: 29523585
Cancers (Basel). 2022 Dec 07;14(24):
pubmed: 36551515
Mol Med Rep. 2015 Dec;12(6):7869-76
pubmed: 26497667
Am J Pathol. 2013 May;182(5):1876-89
pubmed: 23499550
Int J Oncol. 2016 Nov;49(5):1881-1889
pubmed: 27633757
PLoS One. 2013 Nov 01;8(11):e77853
pubmed: 24223734
Genes Dev. 2008 Apr 1;22(7):894-907
pubmed: 18381893
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Curr Med Sci. 2019 Jun;39(3):391-395
pubmed: 31209808
Oncotarget. 2014 Oct 15;5(19):9133-49
pubmed: 25193855
Gynecol Oncol. 2008 Jul;110(1):13-21
pubmed: 18589210
Int J Mol Sci. 2020 Sep 25;21(19):
pubmed: 32993038
Oncogene. 2017 Oct 19;36(42):5840-5851
pubmed: 28628116
J Exp Med. 2019 Mar 4;216(3):688-703
pubmed: 30710055
Cancer Discov. 2011 Jul;1(2):144-57
pubmed: 22303516
Int J Mol Sci. 2021 Mar 26;22(7):
pubmed: 33810259
Oncol Lett. 2021 Apr;21(4):272
pubmed: 33717269
Genes Dev. 2007 May 1;21(9):1025-30
pubmed: 17437991
Trends Cancer. 2020 Nov;6(11):942-950
pubmed: 32680650
FEBS Lett. 2012 May 7;586(9):1279-86
pubmed: 22465665
Dev Cell. 2008 Aug;15(2):272-84
pubmed: 18694566
J Cell Biochem. 2018 Mar;119(3):2484-2491
pubmed: 28836703
Cancer Res. 2012 Dec 15;72(24):6435-46
pubmed: 23074286
J Biol Chem. 2008 May 30;283(22):14910-4
pubmed: 18411277
Cancers (Basel). 2019 Dec 06;11(12):
pubmed: 31817625
Horm Cancer. 2018 Feb;9(1):22-32
pubmed: 29260382
Cell Cycle. 2015;14(3):315-22
pubmed: 25590779
Commun Biol. 2022 Dec 12;5(1):1362
pubmed: 36509990
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Biochimie. 2014 Aug;103:89-100
pubmed: 24769129
Yonsei Med J. 2021 Aug;62(8):691-701
pubmed: 34296546
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11400-5
pubmed: 17600087
PLoS One. 2018 Feb 6;13(2):e0192509
pubmed: 29408861
Nat Commun. 2013;4:2427
pubmed: 24018975
Biochem Genet. 2023 Apr;61(2):506-520
pubmed: 35972581
Nat Rev Mol Cell Biol. 2019 Aug;20(8):457-473
pubmed: 31182865
J Ovarian Res. 2020 Sep 23;13(1):115
pubmed: 32967712
Int J Oncol. 2013 Jul;43(1):63-71
pubmed: 23670532
Mol Cancer Ther. 2008 Jul;7(7):2152-9
pubmed: 18645025